{"id":8014,"date":"2019-12-03T13:43:03","date_gmt":"2019-12-03T18:43:03","guid":{"rendered":"http:\/\/localhost:10028\/uncategorized\/possible-fda-crackdown-against-cbd-products\/"},"modified":"2019-12-03T13:43:03","modified_gmt":"2019-12-03T18:43:03","slug":"possible-fda-crackdown-against-cbd-products","status":"publish","type":"post","link":"https:\/\/napolilaw.lemonadestand.org\/en\/article\/possible-fda-crackdown-against-cbd-products\/","title":{"rendered":"Possible FDA Crackdown Against CBD Products"},"content":{"rendered":"

The Food and Drug Administration told over a dozen companies to stop selling cannabidiol-infused food products and stop making <\/span>inflated health claims<\/span><\/a> about their products.<\/span><\/p>\n

CBD is a non-psychoactive marijuana ingredient which has medicinal properties. Yet the FDA has only approved one CBD product. <\/span><\/p>\n

Epidiolex treats some rare forms of childhood epilepsy. Other CBD products, such as health supplements and edibles, have not been reviewed. <\/span><\/p>\n

Regulators are especially concerned that CBD products, which have not been <\/span>proven safe<\/span><\/a>, are often marketed to infants and children.\u00a0<\/span><\/p>\n

Companies in Arizona, California, Colorado, Florida, New York, and several other states all received warning letters.<\/span><\/p>\n

The FDA Review Process<\/b><\/h2>\n

CBD-infused products have been available for quite some time, even before the 2018 Farm Bill legalized cannabidiol, at least to some extent. But for some reason, regulators have not spoken out against such products until now.<\/span><\/p>\n

For many years, pundits have criticized the FDA for its slow drug and device approval process. <\/span><\/p>\n

Many of these commentators probably had financial links to drug companies that wanted to sell risky medicines and make lots of money, but that\u2019s the subject of another blog.<\/span><\/p>\n

Partially in response to such criticism, regulatory wait time has <\/span>decreased significantly<\/span><\/a> since 1993. <\/span><\/p>\n

For example, so-called priority review times have decreased from nearly two years to just over six months. <\/span><\/p>\n

In fact, wait time is almost nonexistent in fast-track reviews. This drug and device review process covers the following four categories:<\/span><\/p>\n